Inthera Bioscience AG
Inthera Bioscience AG is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Inthera Bioscience AG.
Inthera Bioscience AG is a company.
Key people at Inthera Bioscience AG.
Key people at Inthera Bioscience AG.
Inthera Bioscience AG is a private Swiss biotechnology company developing first-in-class small molecule inhibitors targeting intracellular protein-protein interactions to treat currently incurable cancers.[2][3] Its lead product, INTH-454, is an IND-ready oral small molecule that binds to the Negative Elongation Factor (NELF) complex, disrupting dysregulated transcription, inducing replicative stress, inhibiting DNA synthesis, and selectively killing tumor cells while sparing normal cells.[1][4][6] The company serves oncology patients and the healthcare sector, addressing the challenge of "undruggable" cancer targets essential for tumor proliferation, with its most advanced program in late preclinical development progressing toward clinical trials.[2][3][4] Inthera has raised $14.8M total, including an $11.1M Series A round about 8 years ago from investors like M Ventures and Novo Seeds, positioning it for further advancement in cancer therapeutics.[5]
Founded in 2014, Inthera Bioscience AG emerged from technology linked to NYU's Technology Opportunities & Ventures, with principal investigator Arora involved in its early development.[4] The company originated in Wädenswil, Switzerland (headquarters at Einsiedlerstrasse 34), focusing on novel small chemical molecules that inhibit key cellular processes in high-replication tumor cells.[4][5] Early traction included seed funding from Novo Seeds and a pivotal Series A round of €9.6M ($11.1M) led by M Ventures, enabling progression of its proprietary platform for protein-protein interaction modulators.[3][5] Specific founders are not detailed in available sources, but the company has evolved under leadership like current CEO Mark Krul, building on innovative chemistry to target transcription dysregulation in oncology.[6]
Inthera rides the wave of precision oncology, targeting undruggable protein-protein interactions amid rising demand for therapies against transcriptionally addicted cancers like those with high replication rates.[2][3][4] Timing aligns with advances in chemical biology and AI-driven drug design, where small molecules disrupting intracellular complexes address gaps left by traditional kinase inhibitors.[3] Market forces favoring Inthera include surging oncology R&D investment (global cancer drug market exceeding $200B annually) and regulatory push for novel mechanisms, as seen in IND-ready assets like INTH-454.[6] By pioneering NELF inhibitors, Inthera influences the ecosystem through partnerships with pharma VCs like M Ventures (Merck-linked) and Novo, potentially accelerating similar "undruggable" target platforms in Swiss and global biotech hubs.[3][5]
Inthera is poised for clinical entry with INTH-454, likely pursuing Phase 1 trials in 2026 following IND filing, leveraging its preclinical efficacy in tumor-selective killing.[6] Trends like combination therapies with immunotherapies and AI-optimized small molecules will shape its path, amplifying impact in hard-to-treat solid tumors.[3] Its influence may grow via Big Pharma partnerships or further funding, evolving from preclinical innovator to clinical contender—echoing its founding mission to deliver highly effective therapies against incurable cancers.[2][3]
